57 completed, 27 recruiting, 25 terminated, 20 unknown. 164 Phase 3, 26 Phase 2.
Follow Nephritis: new trials by email Literature Review of Nephritis trials Research Report on Nephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients Pegcetacoplan - C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative | Phase 3 | Not yet recruiting | Swedish Orphan Biovitrum | 30 | 2027-01-21 | 2026-10-27 |
| A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy zigakibart, atrasentan, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 340 | 2026-12-01 | 2026-09-30 |
| A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A Nephropathy JADE101, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Not yet recruiting | Jade Biosciences, Inc. | 480 | 2026-12-01 | 2026-10-29 |
| Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab, Standard of care - IgA Nephropathy | Phase 3 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 24 | 2026-10-30 | 2026-10-15 |
| A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy | Phase 3 | Not yet recruiting | Vertex Pharmaceuticals Incorporated | 40 | 2026-10-23 | 2026-10-22 |
| A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy Inebilizumab, Tacrolimus - Glomerulonephritis, Membranous | Phase 3 | Recruiting | Amgen | 159 | 2026-10-01 | 2026-10-01 |
| A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy Povetacicept - Immunoglobulin A Nephropathy | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 605 | 2026-09-17 | 2026-10-19 |
| A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial) obinutuzumab (RO5072759) - Lupus Nephritis | Phase 3 | Not yet recruiting | Zhao Minghui | 70 | 2026-09-10 | 2026-08-26 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-10-15 |
| A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy BHV-1400, Placebo - IgA Nephropathy | Phase 3 | Not yet recruiting | Biohaven Therapeutics Ltd. | 420 | 2026-06-01 | 2026-06-11 |
| Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN HSK39297, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 370 | 2026-04-07 | 2026-05-28 |
| A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) BI 764198, Placebo - Focal Segmental Glomerulosclerosis | Phase 3 | Recruiting | Boehringer Ingelheim | 286 | 2026-02-16 | 2026-10-28 |
| A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment Cenerimod, Placebo - Nephritis, Lupus, Lupus Erythematosus, Systemic | Phase 3 | Recruiting | Viatris Innovation GmbH | 300 | 2026-02-09 | 2026-07-30 |
| Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy Rituximab combined with cyclosporine, rituximab - Membranous Nephropathy | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 90 | 2026-01-21 | 2026-10-06 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN iptacopan - Primary Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 31 | 2025-11-27 | 2026-09-09 |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis BAT4406F, Placebos - Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 192 | 2025-10-26 | 2026-04-03 |
| Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study Obinutuzumab administration - Membranous Nephropathy - PLA2R Induced | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 20 | 2025-10-01 | 2026-01-06 |
| Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis Telitacicept - IgA Nephropathy (IgAN), IgAVN | Phase 3 | Not yet recruiting | Guixia Ding | 124 | 2025-08-01 | 2025-07-10 |
| Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. zigakibart - Kidney Diseases, Kidney Diseases, Chronic | Phase 3 | Recruiting | Novartis Pharmaceuticals | 220 | 2025-07-28 | 2026-08-17 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
Showing 20 of 164. Sign in to see all of them.
Lupus Nephritis (52) · Glomerulonephritis, IGA (51) · Glomerulonephritis (20) · Lupus Erythematosus, Systemic (19) · Proteinuria (19) · Glomerulonephritis, Membranous (18) · Kidney Diseases (15) · Renal Insufficiency, Chronic (12) · Glomerulosclerosis, Focal Segmental (11) · Pyelonephritis (10) · Autoimmune Diseases (7) · Nephrosis, Lipoid (7) · Urinary Tract Infections (7) · Urologic Diseases (7)
Female Urogenital Diseases (163) · Female Urogenital Diseases and Pregnancy Complications (163) · Male Urogenital Diseases (163) · Urogenital Diseases (162) · Urologic Diseases (157) · Kidney Diseases (149) · Immune System Diseases (127) · Glomerulonephritis (125) · Autoimmune Diseases (118) · Skin and Connective Tissue Diseases (62) · Connective Tissue Diseases (61) · Lupus Erythematosus, Systemic (37) · Pathological Conditions, Signs and Symptoms (29) · Signs and Symptoms (21)
Mycophenolic Acid (21) · Rituximab (18) · Cyclophosphamide (16) · Prednisone (15) · Prednisolone (12) · Methylprednisolone (9) · Tacrolimus (8) · Adrenal Cortex Hormones (7) · Azathioprine (6) · Cyclosporine (6) · AMG623 peptibody (4) · Irbesartan (4) · iptacopan (4) · telitacicept (4) · voclosporin (4)
Novartis Pharmaceuticals (14) · Hoffmann-La Roche (5) · Sun Yat-sen University (5) · Anthera Pharmaceuticals (4) · Aurinia Pharmaceuticals Inc. (4) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4) · Peking Union Medical College Hospital (4) · Radboud University Medical Center (4) · Assistance Publique - Hôpitaux de Paris (3) · Assiut University (3) · Biogen (3) · Genentech, Inc. (3) · Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · Alexion Pharmaceuticals, Inc. (2) · Apellis Pharmaceuticals, Inc. (2)
China (58) · United States (56) · Spain (42) · France (37) · Germany (36) · Italy (33) · South Korea (33) · United Kingdom (32) · Brazil (31) · Czechia (31) · Argentina (30) · Canada (30) · Japan (30) · Taiwan (30) · Australia (29)
Daniel TM Chan, Prof (2) · Fernando C. Fervenza, M.D., Ph.D. (2) · Jack F Wetzels, MD, PhD (2) · Radko Komers, MD, PhD (2) · Yingyos Avihingsanon, MD (2) · Yu Xueqing, MD (2) · A.K. Deb (1)
PMID 38299639, PMID 34778952, PMID 35224732, PMID 37528520, PMID 38864363, PMID 37772889, PMID 40465397, PMID 19670912, PMID 20211892, PMID 21303745, PMID 22087680, PMID 26032537, PMID 26630142, PMID 33159213, PMID 33687069, PMID 33693991, PMID 35675911, PMID 37254256, PMID 39513526, PMID 40337980, PMID 41092316, PMID 42133432, PMID 10093981, PMID 10676716, PMID 11877568, PMID 14694168, PMID 17660026, PMID 17880755, PMID 18042477, PMID 18242357, PMID 18587715, PMID 18668592, PMID 19666912, PMID 19933596, PMID 20039429, PMID 21080348, PMID 21177013, PMID 21178977, PMID 21734640, PMID 21943027, PMID 22231479, PMID 22325903, PMID 22922564, PMID 23675422, PMID 23782179, PMID 24529291, PMID 25757867, PMID 25931244, PMID 26087670, PMID 26629352
2023 (7), 2025 (4), 2018 (2), 2019 (2), 2009 (1), 2016 (1), 2017 (1), U01DK063385 (1), U01DK063455 (1), U01DK063490 (1), U01DK063549 (1)